Merck pulls a patent win for diabetes franchise in West Virginia federal court
Merck doesn’t have to sweat Januvia and Janumet competitors — at least for now.
A federal judge awarded Merck a win in its patent battle against Viatris, the pharma giant announced Thursday, putting the freeze on a potential Viatris generic until at least 2026, barring an appeal.
Judge Irene Keeley of West Virginia upheld two key patents surrounding sitagliptin, an active ingredient in the blockbuster diabetes drugs. The first patent, No. 7,326,708, covers the dihydrogen phosphate salt of sitagliptin and is valid through 2026, with pediatric exclusivity until 2027. The second, No. 8,414,921, covers the co-formulation of sitagliptin and metformin in Janumet and expires in 2029.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.